Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 11/2010

Open Access 01-11-2010 | Original Article

The role of 18F-FDG PET in the differentiation between lung metastases and synchronous second primary lung tumours

Authors: Bernadette G. Dijkman, Olga C. J. Schuurbiers, Dennis Vriens, Monika Looijen-Salamon, Johan Bussink, Johanna N. H. Timmer-Bonte, Miranda M. Snoeren, Wim J. G. Oyen, Henricus F. M. van der Heijden, Lioe-Fee de Geus-Oei

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 11/2010

Login to get access

Abstract

Purpose

In lung cancer patients with multiple lesions, the differentiation between metastases and second primary tumours has significant therapeutic and prognostic implications. The aim of this retrospective study was to investigate the potential of 18F-FDG PET to discriminate metastatic disease from second primary lung tumours.

Methods

Of 1,396 patients evaluated by the thoracic oncology group between January 2004 and April 2009 at the Radboud University Nijmegen Medical Centre, patients with a synchronous second primary lung cancer were selected. Patients with metastatic disease involving the lungs served as the control group. Maximum standardized uptake values (SUVs) measured with 18F-FDG PET were determined for two tumours in each patient. The relative difference between the SUVs of these tumours (∆SUV) was determined and compared between the second primary group and metastatic disease group. Receiver-operating characteristic (ROC) curve analysis was performed to determine the sensitivity and specificity of the ∆SUV for an optimal cut-off value.

Results

A total of 37 patients (21 metastatic disease, 16 second primary cancer) were included for analysis. The ∆SUV was significantly higher in patients with second primary cancer than in those with metastatic disease (58 vs 28%, respectively, p < 0.001). The area under the ROC curve was 0.81 and the odds ratio for the optimal cut-off was 18.4.

Conclusion

SUVs from 18F-FDG PET images can be helpful in differentiating metastatic disease from second primary tumours in patients with synchronous pulmonary lesions. Further studies are warranted to confirm the consistency of these results.
Literature
1.
Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008;83:584–94.CrossRefPubMed
2.
Travis LB. The epidemiology of second primary cancers. Cancer Epidemiol Biomarkers Prev 2006;15:2020–6.CrossRefPubMed
3.
Soerjomataram I, Coebergh JW. Epidemiology of multiple primary cancers. Methods Mol Biol 2009;471:85–105.CrossRefPubMed
4.
van Rens MT, Zanen P, Brutel de La Rivière A, Elbers HR, van Swieten HA, van Den Bosch JM. Survival in synchronous vs. single lung cancer: upstaging better reflects prognosis. Chest 2000;118:952–8.CrossRefPubMed
5.
Battafarano RJ, Meyers BF, Guthrie TJ, Cooper JD, Patterson GA. Surgical resection of multifocal non-small cell lung cancer is associated with prolonged survival. Ann Thorac Surg 2002;74:988–93.CrossRefPubMed
6.
7.
Aguiló R, Macià F, Porta M, Casamitjana M, Minguella J, Novoa AM. Multiple independent primary cancers do not adversely affect survival of the lung cancer patient. Eur J Cardiothorac Surg 2008;34:1075–80.CrossRefPubMed
8.
Douglas WG, Rigual NR, Loree TR, Wiseman SM, Al-Rawi S, Hicks Jr WL. Current concepts in the management of a second malignancy of the lung in patients with head and neck cancer. Curr Opin Otolaryngol Head Neck Surg 2003;11:85–8.CrossRefPubMed
9.
Silvestri GA, Gould MK, Margolis ML, Tanoue LT, McCrory D, Toloza E, et al. Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest 2007;132:178S–201.CrossRefPubMed
10.
Leong PP, Rezai B, Koch WM, Reed A, Eisele D, Lee DJ, et al. Distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma. J Natl Cancer Inst 1998;90:972–7.CrossRefPubMed
11.
Koppe MJ, Zoetmulder FA, van Zandwijk N, Hart AA, Baas P, Rutgers EJ. The prognostic significance of a previous malignancy in operable non-small cell lung cancer. Lung Cancer 2001;32:47–53.CrossRefPubMed
12.
Chang YL, Wu CT, Lee YC. Surgical treatment of synchronous multiple primary lung cancers: experience of 92 patients. J Thorac Cardiovasc Surg 2007;134:630–7.CrossRefPubMed
13.
Chhieng DC, Cangiarella JF, Zakowski MF, Goswami S, Cohen JM, Yee HT. Use of thyroid transcription factor 1, PE-10, and cytokeratins 7 and 20 in discriminating between primary lung carcinomas and metastatic lesions in fine-needle aspiration biopsy specimens. Cancer 2001;93:330–6.CrossRefPubMed
14.
van Oijen MG, Leppers Vd Straat FG, Tilanus MG, Slootweg PJ. The origins of multiple squamous cell carcinomas in the aerodigestive tract. Cancer 2000;88:884–93.CrossRefPubMed
15.
van Rens MT, Eijken EJ, Elbers JR, Lammers JW, Tilanus MG, Slootweg PJ. p53 mutation analysis for definite diagnosis of multiple primary lung carcinoma. Cancer 2002;94:188–96.CrossRefPubMed
16.
de Geus-Oei LF, van Krieken JH, Aliredjo RP, Krabbe PF, Frielink C, Verhagen AF, et al. Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer 2007;55:79–87.CrossRefPubMed
17.
Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg 2005;130:151–9.CrossRefPubMed
18.
Jeong HJ, Min JJ, Park JM, Chung JK, Kim BT, Jeong JM, et al. Determination of the prognostic value of [(18)F]fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer. Nucl Med Commun 2002;23:865–70.CrossRefPubMed
19.
Vesselle H, Salskov A, Turcotte E, Wiens L, Schmidt R, Jordan CD, et al. Relationship between non-small cell lung cancer FDG uptake at PET, tumor histology, and Ki-67 proliferation index. J Thorac Oncol 2008;3:971–8.CrossRefPubMed
20.
Higashi K, Ueda Y, Ayabe K, Sakurai A, Seki H, Nambu Y, et al. FDG PET in the evaluation of the aggressiveness of pulmonary adenocarcinoma: correlation with histopathological features. Nucl Med Commun 2000;21:707–14.CrossRefPubMed
21.
Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med 2007;48:932–45.CrossRefPubMed
22.
23.
Jeon SY, Ahn SH, Kim CH, Lim SM, Koh JS, Lee JC. Esophageal and laryngeal cancer incidentally found on [18F]fluorodeoxyglucose positron emission tomography/computed tomography during the staging workup for lung cancer. Clin Lung Cancer 2008;9:230–1.CrossRefPubMed
24.
Mittra E, Vasanawala M, Niederkohr R, Rodriguez C, Segall G. A case of three synchronous primary tumors demonstrated by F-18 FDG PET. Clin Nucl Med 2007;32:666–7.CrossRefPubMed
25.
van Westreenen HL, Westerterp M, Jager PL, van Dullemen HM, Sloof GW, Comans EF, et al. Synchronous primary neoplasms detected on 18F-FDG PET in staging of patients with esophageal cancer. J Nucl Med 2005;46:1321–5.PubMed
26.
Adriaensen M, Schijf L, de Haas M, Huijbregts J, Baarslag HJ, Staaks G, et al. Six synchronous primary neoplasms detected by FDG-PET/CT. Eur J Nucl Med Mol Imaging 2008;35:1931.CrossRefPubMed
27.
Obando JA, Samii JM, Yasrebi M. A case of two synchronous primary lung tumors demonstrated by FDG positron emission tomography. Clin Nucl Med 2008;33:775–7.CrossRefPubMed
28.
Wilkinson MD, Fulham MJ, McCaughan BC, Constable CJ. Differentiation of synchronous tumors using FDG positron emission tomography. Clin Nucl Med 2003;28:489–91.CrossRefPubMed
29.
Aquino SL, Halpern EF, Kuester LB, Fischman AJ. FDG-PET and CT features of non-small cell lung cancer based on tumor type. Int J Mol Med 2007;19:495–9.PubMed
30.
Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 2001;285:914–24.CrossRefPubMed
31.
Gould MK, Kuschner WG, Rydzak CE, Maclean CC, Demas AN, Shigemitsu H, et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med 2003;139:879–92.PubMed
32.
de Geus-Oei LF, van der Heijden HF, Corstens FH, Oyen WH. Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: a systematic review. Cancer 2007;110:1654–64.CrossRefPubMed
33.
MacManus M, Nestle U, Rosenzweig KE, Carrio I, Messa C, Belohlavek O, et al. Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006–2007. Radiother Oncol 2009;91:85–94.CrossRefPubMed
34.
Degirmenci B, Wilson D, Laymon CM, Becker C, Mason NS, Bencherif B, et al. Standardized uptake value-based evaluations of solitary pulmonary nodules using F-18 fluorodeoxyglucose-PET/computed tomography. Nucl Med Commun 2008;29:614–22.CrossRefPubMed
35.
de Geus-Oei LF, van der Heijden HF, Visser EP, Hermsen R, van Hoorn BA, Timmer-Bonte JN, et al. Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer. J Nucl Med 2007;48:1592–8.CrossRefPubMed
36.
Schuurbiers OC, Kaanders JH, van der Heijden HF, Dekhuijzen RP, Oyen WJ, Bussink J. The PI3-K/AKT-pathway and radiation resistance mechanisms in non-small cell lung cancer. J Thorac Oncol 2009;4:761–7.CrossRefPubMed
37.
Jaskowiak CJ, Bianco JA, Perlman SJ, Fine JP. Influence of reconstruction iterations on 18F-FDG PET/CT standardized uptake values. J Nucl Med 2005;46:424–8.PubMed
38.
Lammertsma AA, Hoekstra CJ, Giaccone G, Hoekstra OS. How should we analyse FDG PET studies for monitoring tumour response? Eur J Nucl Med Mol Imaging 2006;33 Suppl 1:16–21.CrossRefPubMed
39.
Nakamoto Y, Zasadny KR, Minn H, Wahl RL. Reproducibility of common semi-quantitative parameters for evaluating lung cancer glucose metabolism with positron emission tomography using 2-deoxy-2-[18F]fluoro-D-glucose. Mol Imaging Biol 2002;4:171–8.CrossRefPubMed
40.
Nahmias C, Wahl LM. Reproducibility of standardized uptake value measurements determined by 18F-FDG PET in malignant tumors. J Nucl Med 2008;49:1804–8.CrossRefPubMed
41.
Kim CK, Gupta NC, Chandramouli B, Alavi A. Standardized uptake values of FDG: body surface area correction is preferable to body weight correction. J Nucl Med 1994;35:164–7.PubMed
42.
Sobin LH, Wittekind C, editors. TNM classification of malignant tumours (UICC). 6th ed. New York: Wiley; 2002.
Metadata
Title
The role of 18F-FDG PET in the differentiation between lung metastases and synchronous second primary lung tumours
Authors
Bernadette G. Dijkman
Olga C. J. Schuurbiers
Dennis Vriens
Monika Looijen-Salamon
Johan Bussink
Johanna N. H. Timmer-Bonte
Miranda M. Snoeren
Wim J. G. Oyen
Henricus F. M. van der Heijden
Lioe-Fee de Geus-Oei
Publication date
01-11-2010
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 11/2010
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-010-1505-2

Other articles of this Issue 11/2010

European Journal of Nuclear Medicine and Molecular Imaging 11/2010 Go to the issue

Original Article

Imaging with radiolabelled anti-membrane type 1 matrix metalloproteinase (MT1-MMP) antibody: potentials for characterizing atherosclerotic plaques

Original Article

Reduced dimethylaminoethanol in [18F]fluoromethylcholine: an important step towards enhanced tumour visualization

Letter to the Editor

Methodological issues in the evaluation of FDG PET/CT accuracy in pediatric lymphoma

Society Communications

EANM Springer Prizes 2010 Awarded

Erratum

Erratum to: Comparison of two neural network classifiers in the differential diagnosis of essential tremor and Parkinson’s disease by 123I-FP-CIT brain SPECT

Original Article

PET/CT-guided biopsies of metabolically active bone lesions: applications and clinical impact